These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 21606442)

  • 1. Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation.
    Tammemagi CM; Pinsky PF; Caporaso NE; Kvale PA; Hocking WG; Church TR; Riley TL; Commins J; Oken MM; Berg CD; Prorok PC
    J Natl Cancer Inst; 2011 Jul; 103(13):1058-68. PubMed ID: 21606442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of adverse smoking outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Barry SA; Tammemagi MC; Penek S; Kassan EC; Dorfman CS; Riley TL; Commin J; Taylor KL
    J Natl Cancer Inst; 2012 Nov; 104(21):1647-59. PubMed ID: 23104210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.
    Katki HA; Kovalchik SA; Berg CD; Cheung LC; Chaturvedi AK
    JAMA; 2016 Jun; 315(21):2300-11. PubMed ID: 27179989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Hocking WG; Hu P; Oken MM; Winslow SD; Kvale PA; Prorok PC; Ragard LR; Commins J; Lynch DA; Andriole GL; Buys SS; Fouad MN; Fuhrman CR; Isaacs C; Yokochi LA; Riley TL; Pinsky PF; Gohagan JK; Berg CD;
    J Natl Cancer Inst; 2010 May; 102(10):722-31. PubMed ID: 20442215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.
    Ten Haaf K; Jeon J; Tammemägi MC; Han SS; Kong CY; Plevritis SK; Feuer EJ; de Koning HJ; Steyerberg EW; Meza R
    PLoS Med; 2017 Apr; 14(4):e1002277. PubMed ID: 28376113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of true positive lung cancers in individuals with abnormal suspicious chest radiographs: a prostate, lung, colorectal, and ovarian cancer screening trial study.
    Tammemagi MC; Freedman MT; Pinsky PF; Oken MM; Hu P; Riley TL; Ragard LR; Berg CD; Prorok PC
    J Thorac Oncol; 2009 Jun; 4(6):710-21. PubMed ID: 19404219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.
    Tammemagi MC; Schmidt H; Martel S; McWilliams A; Goffin JR; Johnston MR; Nicholas G; Tremblay A; Bhatia R; Liu G; Soghrati K; Yasufuku K; Hwang DM; Laberge F; Gingras M; Pasian S; Couture C; Mayo JR; Nasute Fauerbach PV; Atkar-Khattra S; Peacock SJ; Cressman S; Ionescu D; English JC; Finley RJ; Yee J; Puksa S; Stewart L; Tsai S; Haider E; Boylan C; Cutz JC; Manos D; Xu Z; Goss GD; Seely JM; Amjadi K; Sekhon HS; Burrowes P; MacEachern P; Urbanski S; Sin DD; Tan WC; Leighl NB; Shepherd FA; Evans WK; Tsao MS; Lam S;
    Lancet Oncol; 2017 Nov; 18(11):1523-1531. PubMed ID: 29055736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung Cancer Risk and Demographic Characteristics of Current 20-29 Pack-year Smokers: Implications for Screening.
    Pinsky PF; Kramer BS
    J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26483244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dietary carbohydrate, glycemic index, glycemic load, and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) cohort.
    Shikany JM; Flood AP; Kitahara CM; Hsing AW; Meyer TE; Willcox BJ; Redden DT; Ziegler RG
    Cancer Causes Control; 2011 Jul; 22(7):995-1002. PubMed ID: 21553078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial.
    Lotan Y; Karam JA; Shariat SF; Gupta A; Roupret M; Bensalah K; Margulis V
    Urol Oncol; 2016 Apr; 34(4):167.e9-16. PubMed ID: 26602092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deep Learning Using Chest Radiographs to Identify High-Risk Smokers for Lung Cancer Screening Computed Tomography: Development and Validation of a Prediction Model.
    Lu MT; Raghu VK; Mayrhofer T; Aerts HJWL; Hoffmann U
    Ann Intern Med; 2020 Nov; 173(9):704-713. PubMed ID: 32866413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung cancer risk by years since quitting in 30+ pack year smokers.
    Pinsky PF; Zhu CS; Kramer BS
    J Med Screen; 2015 Sep; 22(3):151-7. PubMed ID: 25926339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OWL: an optimized and independently validated machine learning prediction model for lung cancer screening based on the UK Biobank, PLCO, and NLST populations.
    Pan Z; Zhang R; Shen S; Lin Y; Zhang L; Wang X; Ye Q; Wang X; Chen J; Zhao Y; Christiani DC; Li Y; Chen F; Wei Y
    EBioMedicine; 2023 Feb; 88():104443. PubMed ID: 36701900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Oken MM; Marcus PM; Hu P; Beck TM; Hocking W; Kvale PA; Cordes J; Riley TL; Winslow SD; Peace S; Levin DL; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Dec; 97(24):1832-9. PubMed ID: 16368945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection criteria for lung-cancer screening.
    Tammemägi MC; Katki HA; Hocking WG; Church TR; Caporaso N; Kvale PA; Chaturvedi AK; Silvestri GA; Riley TL; Commins J; Berg CD
    N Engl J Med; 2013 Feb; 368(8):728-36. PubMed ID: 23425165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
    Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
    J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer.
    Pine SR; Mechanic LE; Enewold L; Chaturvedi AK; Katki HA; Zheng YL; Bowman ED; Engels EA; Caporaso NE; Harris CC
    J Natl Cancer Inst; 2011 Jul; 103(14):1112-22. PubMed ID: 21685357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selecting High-Risk Individuals for Lung Cancer Screening: A Prospective Evaluation of Existing Risk Models and Eligibility Criteria in the German EPIC Cohort.
    Li K; Hüsing A; Sookthai D; Bergmann M; Boeing H; Becker N; Kaaks R
    Cancer Prev Res (Phila); 2015 Sep; 8(9):777-85. PubMed ID: 26076698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography Lung Cancer Screening.
    Katki HA; Kovalchik SA; Petito LC; Cheung LC; Jacobs E; Jemal A; Berg CD; Chaturvedi AK
    Ann Intern Med; 2018 Jul; 169(1):10-19. PubMed ID: 29800127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.